Optic Neuritis
Optic neuritis (ON) is an inflammatory demyelinating disorder of the optic nerve that represents one of the most common causes of acute vision loss in young adults. It is the presenting manifestation of multiple sclerosis (MS) in approximately 20% of cases and occurs during the disease course in up to 50%. The landscape of optic neuritis has been transformed by the recognition of antibody-mediated forms associated with aquaporin-4 IgG (AQP4-IgG) and myelin oligodendrocyte glycoprotein IgG (MOG-IgG), which carry distinct prognostic and therapeutic implications. The Optic Neuritis Treatment Trial (ONTT) remains the foundational study informing acute management, while emerging biomarkers and imaging modalities have refined the diagnostic approach for practicing neurologists.
Bottom Line
- Typical ON: Unilateral, painful vision loss in a young adult (20–45 years) with an RAPD, dyschromatopsia, and central/cecocentral scotoma — most commonly associated with MS
- ONTT landmark findings: IV methylprednisolone (250 mg q6h × 3 days then oral taper) hastens visual recovery but does not change the final visual outcome at 1 year; oral prednisone (1 mg/kg/day) alone increases the risk of recurrence and should never be used as monotherapy
- MS risk stratification: The 15-year ONTT follow-up showed that baseline brain MRI is the strongest predictor of MS — 72% with ≥1 white matter lesion developed MS vs. 25% with a normal MRI
- Antibody-mediated ON: MOG-IgG ON tends to cause severe disc edema with good recovery but high relapse risk; AQP4-IgG ON preferentially involves the posterior optic nerve/chiasm with worse visual outcomes
- Atypical features: Painless onset, no light perception vision, bilateral simultaneous involvement, age >50 or <15, lack of recovery by 4 weeks, or progressive course should prompt evaluation for alternative diagnoses
- OCT: Retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thinning on optical coherence tomography (OCT) quantify axonal loss and predict long-term visual function
Epidemiology and Etiology
Optic neuritis has an annual incidence of approximately 1–5 per 100,000 in Western populations, with a female predominance of roughly 3:1. Peak onset occurs between 20 and 45 years of age. It is most common in White populations and in higher latitudes, paralleling the epidemiology of MS. The three major etiologic categories are:
- MS-associated ON: The most common form in clinical practice; typically unilateral, retrobulbar, with good recovery
- MOG-IgG associated ON: Accounts for approximately 25–40% of AQP4-IgG-seronegative "atypical" ON; more common in males and children than MS-ON
- AQP4-IgG associated ON (NMOSD): Severe, often bilateral or sequential, with posterior optic pathway involvement; female predominance 9:1
- Other causes: Sarcoidosis, systemic lupus erythematosus, infections (syphilis, Lyme, viral), post-vaccination, paraneoplastic (CRMP-5/CV2)
Clinical Features
Typical Optic Neuritis (MS-Associated)
The hallmark presentation is subacute, unilateral, painful vision loss developing over hours to days, with nadir typically reached within 1–2 weeks.
- Pain: Periorbital or retro-orbital pain exacerbated by eye movement, present in ≥90% of cases; often precedes or accompanies visual loss
- Visual acuity: Variable, ranging from 20/20 to no light perception (NLP); most patients have moderate acuity loss (20/25 to 20/200)
- Relative afferent pupillary defect (RAPD): Present in virtually all unilateral cases; the single most important examination finding
- Dyschromatopsia: Impaired color vision, often disproportionate to acuity loss — red desaturation is the most sensitive bedside test
- Visual field defect: Central or cecocentral scotoma most common; diffuse depression, arcuate, and altitudinal defects also occur
- Funduscopy: Normal optic disc in two-thirds of cases (retrobulbar neuritis — "the patient sees nothing, the doctor sees nothing"); one-third show disc edema (papillitis)
- Uhthoff phenomenon: Transient worsening of vision with heat exposure or exercise, present in up to 50% during recovery
- Pulfrich phenomenon: Asymmetric conduction delay between eyes causing misperception of moving objects' trajectory
Typical vs. Atypical Optic Neuritis
- Typical ON (suggests MS): Unilateral, painful, age 20–45, retrobulbar (normal disc), RAPD, good recovery within 4–6 weeks
- Atypical ON (investigate further): Bilateral simultaneous, painless, age <15 or >50, no recovery by 4 weeks, progressive course, NLP vision, severe disc edema with hemorrhages, macular star, uveitis
- Key principle: Atypical features mandate expanded workup for NMOSD (AQP4-IgG), MOGAD (MOG-IgG), sarcoidosis, infections, and compressive/neoplastic etiologies
MOG-IgG Associated Optic Neuritis
- Demographics: More equal sex distribution (F:M ~1:1); bimodal age distribution with pediatric and adult peaks
- Prominent disc edema: More frequent and severe than MS-ON; may mimic papilledema or anterior ischemic optic neuropathy
- Bilateral involvement: Simultaneous or rapidly sequential bilateral ON more common than in MS
- MRI pattern: Long segment of anterior optic nerve enhancement (>50% of nerve length), perineural enhancement ("optic perineuritis" pattern)
- Visual loss: Can be severe at nadir but typically recovers well with treatment
- Relapse risk: ~50% have relapsing course; relapse risk higher with persistent MOG-IgG seropositivity
- OCT: Relatively preserved GCIPL compared with RNFL thinning (optic nerve head edema contributes to apparent RNFL loss acutely)
AQP4-IgG Associated Optic Neuritis (NMOSD)
- Demographics: Marked female predominance (9:1); higher prevalence in non-White populations; peak age 30–50 years
- Posterior optic pathway: Preferential involvement of the optic chiasm and intracranial optic nerve segments
- Severe vision loss: Profound visual loss at nadir is common; NLP occurs more frequently than in MS-ON or MOGAD-ON
- Poor recovery: Significant residual visual deficit is the rule rather than the exception; legal blindness in the affected eye common
- Bilateral sequential involvement: Risk of fellow eye involvement is high without prophylactic immunosuppression
- MRI: Enhancement of the posterior optic nerve, chiasm, and/or optic tracts; may show chiasmal thickening
- OCT: Severe RNFL thinning with marked GCIPL loss, reflecting extensive axonal damage
Differential Diagnosis
| Diagnosis | Key Distinguishing Features | Helpful Investigations |
|---|---|---|
| NAION | Painless; age >50; altitudinal field defect; disc edema with splinter hemorrhages; "disc at risk" in fellow eye | Cardiovascular risk factors; ESR/CRP to exclude GCA |
| Compressive optic neuropathy | Progressive, painless vision loss; proptosis; optic disc pallor or edema; motility disturbance | MRI orbits and brain with contrast; consider meningioma, glioma, pituitary adenoma |
| Leber hereditary optic neuropathy (LHON) | Painless, sequential bilateral vision loss in young males; peripapillary telangiectasia; no leak on FA; maternal inheritance | Mitochondrial DNA testing (m.11778G>A, m.3460G>A, m.14484T>C) |
| Sarcoidosis | Optic perineuritis pattern; uveitis; may be bilateral; granulomatous enhancement | ACE, chest CT, PET scan, biopsy of accessible tissue |
| Neurosyphilis | Optic neuritis, papillitis, or neuroretinitis; may have Argyll Robertson pupils | RPR/VDRL, FTA-ABS; CSF VDRL |
| Neuroretinitis | Disc edema with macular star exudates; usually infectious (Bartonella, syphilis, Lyme) | Bartonella serology, infectious workup; NOT associated with MS |
| Central serous retinopathy | Painless blurred vision; metamorphopsia; serous macular detachment on OCT; no RAPD | OCT macula; fluorescein angiography |
The Optic Neuritis Treatment Trial (ONTT)
The ONTT (enrolled 1988–1991, n=457) is the landmark study that established the evidence base for acute ON management and defined the natural history and MS risk associated with a first episode of ON. Its findings remain the cornerstone of clinical decision-making.
Study Design
Three randomized treatment arms: (1) oral prednisone 1 mg/kg/day × 14 days, (2) IV methylprednisolone 250 mg q6h × 3 days followed by oral prednisone 1 mg/kg/day × 11 days, and (3) oral placebo × 14 days. Follow-up extended to 15 years (ONTT Long-Term Follow-Up Study, published 2008).
ONTT Key Findings
- IV steroids hasten recovery: Significantly faster visual recovery in the first 4–6 weeks compared with placebo or oral prednisone
- No long-term visual benefit: At 6 months and beyond, visual acuity outcomes were equivalent across all three groups — final visual outcome is the same regardless of treatment
- Oral prednisone alone increases recurrence: The oral prednisone group had a significantly higher rate of new ON episodes (recurrence rate 27% vs. 15% for IV steroids at 2 years) — oral prednisone monotherapy is contraindicated
- Visual recovery is excellent: 95% of patients recovered to 20/40 or better by 1 year, regardless of initial acuity
- Low-contrast sensitivity: Despite good Snellen acuity recovery, many patients have persistent deficits in contrast sensitivity, color vision, and visual field that affect quality of life
Critical ONTT Rule
- Never use oral prednisone alone for acute optic neuritis. The ONTT demonstrated that oral prednisone monotherapy (without preceding IV steroids) paradoxically doubles the rate of recurrent ON. This remains one of the most board-tested principles in neuro-ophthalmology.
- If steroids are to be used, the regimen is IV methylprednisolone first, optionally followed by an oral taper.
- Observation without treatment is also a valid option given that the long-term visual outcome is the same.
ONTT Long-Term MS Risk Data (15-Year Follow-Up)
| Baseline Brain MRI | 15-Year MS Risk |
|---|---|
| Normal brain MRI (no white matter lesions) | 25% |
| ≥1 white matter lesion | 72% |
| Overall (all patients) | 50% |
Additional risk factors for MS conversion: female sex, younger age, recurrent ON episodes, and the presence of periventricular lesions on brain MRI. Notably, neither the severity of initial visual loss nor the type of visual field defect predicted MS risk.
Diagnostic Workup
Imaging
- MRI orbits with fat suppression and gadolinium: The most important imaging study; demonstrates optic nerve enhancement and/or T2 hyperintensity in ~95% of acute ON. STIR and post-contrast fat-suppressed T1 sequences are essential.
- MRI brain: Mandatory for MS risk stratification. The presence and number of T2/FLAIR white matter lesions is the single best predictor of future MS development.
- MRI spinal cord: Consider if there are clinical features suggesting myelopathy or if NMOSD/MOGAD is suspected (look for longitudinally extensive lesions).
- Optic nerve length of enhancement: Long-segment enhancement (>50% nerve length) favors MOGAD; posterior/chiasmal enhancement favors NMOSD; short anterior enhancement is typical of MS-ON.
Optical Coherence Tomography (OCT)
OCT in Optic Neuritis
- Acute phase: RNFL may be thickened (edema) in papillitis; GCIPL thinning begins within 2 weeks and is detectable before RNFL thinning in retrobulbar ON
- Chronic phase (3–6 months post-episode): RNFL thinning ≥20 μm from baseline correlates with clinically significant visual loss; RNFL <75 μm indicates severe axonal loss
- Prognostic value: GCIPL thinning ≥4 μm within the first month predicts poor visual recovery
- Inter-eye difference: RNFL asymmetry ≥5 μm between eyes in MS suggests subclinical ON in the apparently unaffected eye
- Temporal RNFL: The papillomacular bundle (temporal quadrant) is most vulnerable in ON; temporal RNFL thinning is the hallmark chronic OCT finding
Visual Evoked Potentials (VEP)
- P100 latency prolongation: The classic finding; reflects demyelination of the optic nerve. Prolongation persists indefinitely after ON, even with full visual recovery.
- Sensitivity: ~95% in acute ON; remains abnormal in ~70% of eyes with prior ON even years later
- Clinical utility: Most useful for detecting subclinical ON (DIS criterion for MS) in the clinically unaffected eye; less important for diagnosing acute ON (clinical diagnosis)
Laboratory Testing
| Test | Indication | Notes |
|---|---|---|
| AQP4-IgG (cell-based assay) | All atypical ON; bilateral ON; severe vision loss; posterior/chiasmal enhancement | Serum preferred; ~100% specific by CBA |
| MOG-IgG (cell-based assay) | All atypical ON; prominent disc edema; bilateral ON; recurrent ON without MS features | Serum; live CBA preferred; titers correlate with relapse risk |
| CBC, CMP, ESR, CRP | Age >50 (exclude GCA); atypical features | ESR >50 mm/hr and elevated CRP suggest GCA |
| ACE, chest imaging | Suspected sarcoidosis | Low sensitivity; PET or biopsy if high clinical suspicion |
| RPR/FTA-ABS | High-risk patients; atypical features; neuroretinitis | CSF VDRL if neurosyphilis suspected |
| Lyme serology | Endemic area; tick exposure; cranial neuropathies | Two-tier testing algorithm |
| Mitochondrial DNA | Young male; painless bilateral vision loss; family history | Three primary LHON mutations |
| Lumbar puncture | Atypical ON; MS diagnosis (OCBs); suspected infection/inflammation | OCBs present in >85% of MS; absent in most NMOSD/MOGAD |
Comparison of ON Subtypes by Antibody Status
| Feature | MS-Associated ON | MOG-IgG ON | AQP4-IgG ON |
|---|---|---|---|
| Age at onset | 20–45 years | Bimodal (children + adults) | 30–50 years |
| Sex ratio (F:M) | 3:1 | ~1:1 | 9:1 |
| Laterality | Unilateral | Bilateral common | Unilateral or sequential bilateral |
| Pain | Present (>90%) | Present (>80%) | Variable (less with posterior involvement) |
| Disc appearance | Normal (retrobulbar) in 65% | Prominent edema in >80% | Variable |
| MRI pattern | Short, anterior, intraorbital | Long, anterior, perineural sheath enhancement | Posterior, chiasmal, intracranial |
| Nadir severity | Mild to moderate | Severe (often ≤20/200) | Severe (often NLP) |
| Recovery | Good (95% to 20/40) | Good (with treatment) | Poor; significant residual deficit |
| Relapse risk | Moderate (depends on MS activity) | ~50% relapsing | High without immunosuppression |
| OCBs | >85% | <20% | <20% |
Treatment
Acute Management
- IV methylprednisolone: 1 g/day (or 250 mg q6h) × 3–5 days, with or without an oral prednisone taper (1 mg/kg/day × 11 days). This is the standard regimen derived from the ONTT.
- Observation: A valid option for mild MS-associated ON given that long-term visual outcome is unchanged. The decision to treat is primarily to hasten recovery and for patient comfort.
- Oral bioequivalent steroids: High-dose oral methylprednisolone (1,250 mg/day) or oral prednisone equivalent may be noninferior to IV, based on limited comparative studies, but this approach is not yet universally accepted.
- NMOSD-related ON: Requires aggressive treatment — IV methylprednisolone 1 g/day × 5 days, followed by plasma exchange (PLEX, 5–7 exchanges) if no improvement. Early PLEX improves visual outcomes.
- MOGAD-related ON: IV methylprednisolone 1 g/day × 5 days, with a prolonged oral taper (≥3–6 months) to prevent early relapse. PLEX for refractory cases. Short steroid tapers are associated with high relapse rates.
Treatment Pitfalls
- Never use oral prednisone alone as initial treatment for optic neuritis (ONTT demonstrated increased recurrence risk)
- Do not start MS DMTs in AQP4-NMOSD: Interferons, fingolimod, and natalizumab worsen NMOSD; confirm antibody status before initiating MS therapies
- MOGAD steroid dependence: Rapid steroid tapers in MOGAD-ON lead to early relapse; taper slowly over months
- Delay in PLEX for NMOSD: Early plasma exchange (within 2 weeks of onset) significantly improves visual outcomes in AQP4-ON; do not wait for steroid failure
Long-Term Disease-Modifying Therapy
| Condition | Long-Term Therapy | Notes |
|---|---|---|
| MS-associated ON | MS disease-modifying therapies per guidelines | Initiation after first ON with brain lesions reduces MS conversion (CHAMPS, ETOMS, BENEFIT trials) |
| AQP4-NMOSD | Eculizumab, inebilizumab, satralizumab; or rituximab, azathioprine, mycophenolate | Lifelong immunosuppression required; FDA-approved agents preferred |
| MOGAD (relapsing) | Rituximab, IVIG, azathioprine, mycophenolate | No FDA-approved therapy; treat if relapsing or persistent antibody positivity; monophasic disease may not need chronic therapy |
Prognosis
Visual Outcomes
- MS-associated ON: Excellent — 95% recover to 20/40 or better by 1 year (ONTT data). However, subclinical deficits in contrast sensitivity, color vision, and visual field persist and affect quality of life.
- MOG-IgG ON: Generally good recovery with treatment, though recurrent episodes can cause cumulative damage. RNFL loss is typically mild after the first episode but increases with relapses.
- AQP4-IgG ON: Poor visual outcomes — significant residual visual deficit in >50% of affected eyes. Median visual acuity after attack is 20/200 or worse. Early aggressive treatment (steroids + PLEX) improves but does not normalize outcomes.
Risk of Recurrence
- MS-associated: ~35% recurrence in the same eye by 15 years; ~48% in either eye (ONTT data)
- MOGAD: ~50% relapsing course; persistent MOG-IgG seropositivity predicts relapse
- NMOSD: >90% relapsing without immunosuppression; median annualized relapse rate ~1.5
Board-Relevant Clinical Pearls
- Neuroretinitis (disc edema + macular star exudate) is NOT associated with MS and should prompt an infectious workup (especially Bartonella henselae)
- Bilateral simultaneous ON in an adult is atypical for MS and should raise suspicion for MOGAD, NMOSD, or sarcoidosis
- Painless ON with poor recovery in a young male suggests LHON; check mitochondrial DNA mutations
- The fellow eye: In typical ON with a normal fellow eye, occult GCIPL thinning on OCT in the unaffected eye can provide evidence of dissemination in space for MS diagnosis
- Marcus Gunn pupil: An RAPD may be the only examination finding in retrobulbar ON with normal funduscopy and near-normal acuity — always perform the swinging flashlight test
- Uhthoff phenomenon: Not pathognomonic for ON/MS; can occur with any cause of optic nerve conduction delay but is most classically associated with demyelination
Emerging Concepts
- Serum neurofilament light chain (NfL): Elevated in acute ON; correlates with the degree of axonal injury and may predict visual outcomes and MS conversion risk
- GCIPL as an outcome measure: Increasingly used in clinical trials as a structural endpoint for neuroprotection studies in ON (e.g., RENEW, SYNERGY trials)
- Neuroprotection trials: Ongoing studies evaluating erythropoietin, phenytoin, simvastatin, and clemastine for neuroprotection in acute ON, based on the concept of preserving retinal ganglion cells during the inflammatory insult
- MOG-IgG titers: Declining or seroconverting-to-negative MOG-IgG titers predict monophasic disease; persistent positivity predicts relapsing course, guiding long-term treatment decisions
- 7T MRI: Ultra-high-field MRI can visualize optic nerve lesions with greater sensitivity and may detect subtle chiasmal involvement missed at 1.5/3T
References
- Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-732.
- Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581-588.
- Chen JJ, Pittock SJ, Flanagan EP, et al. Optic neuritis in the era of biomarkers. Surv Ophthalmol. 2020;65(1):12-17.
- Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022;21(12):1120-1134.
- Sechi E. NMOSD and MOGAD. Continuum (Minneap Minn). 2024;30(4):1052-1090.
- Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13(1):83-99.
- Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797-812.
- Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134.
- Bennett JL, Costello F, Chen JJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22(1):89-100.
- Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis (CHAMPS Study). N Engl J Med. 2000;343(13):898-904.
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
- Hickman SJ, Dalton CM, Miller DH, et al. Management of acute optic neuritis. Lancet. 2002;360(9349):1953-1962.